Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment-ON DEMAND

ACCP Virtual Journal Club Webinars

On Demand: March 16, 2022 to March 16, 2025

See Handouts tab for Continuing Education information on CME and CPE credits.

Why is this webinar important to you? 

Brexpiprazole is an oral antipsychotic agent indicated for use in patients with schizophrenia or as adjunctive treatment for major depressive disorder.
As obesity (body mass index ≥35 kg/m2) has the potential to affect drug pharmacokinetics and is a common comorbidity of both schizophrenia
and major depressive disorder, it is important to understand changes in brexpiprazole disposition in this population. This study uses a whole-body
physiologically-based pharmacokinetic (PBPK) model to compare the pharmacokinetics of brexpiprazole in obese and normal-weight (body mass index 18-
25 kg/m2) individuals known to be cytochrome P450 2D6 extensive metabolizers and poor metabolizers (PMs).

Target Audience
Physicians, Pharmacists, PhDs and Physician Assistants.

Learning Objectives
After completing this activity, the learner will be able to: 

1) Explain the relationship between obesity, Brexpiprazole pharmacokinetics  and clinical outcome;
2) Articulate the relationship between PMs, Brexpiprazole dosing and clinical outcome;
3) Learn about the PBPK model.

To receive credit, learners must attend the complete live webinar or view the complete on-demand webinar; complete a post-course assessment and evaluation.